Advertisement
BIIB vs PFE
Which Stock Would AI Choose? Biogen (BIIB) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Biogen (BIIB) has returned to double-digit revenue growth, driven by its newer "growth portfolio," while Pfizer (PFE) continues to manage a multi-year patent expiration cliff on blockbuster drugs such as Eliquis and Ibrance.
- Biogen reported an 11% year-over-year revenue increase in its latest quarter and raised the lower end of its full-year earnings guidance, signaling improving business momentum.
- Pfizer offers a substantially higher dividend yield (roughly 5.8%) and recently reached a 52-week high, but Wall Street's consensus rating remains "Hold" amid near-term earnings declines.
- Tickeron AI Verdict: Based on trend consistency, relative momentum, and catalyst positioning, the AI currently favors Biogen (BIIB) over Pfizer (PFE) in this stock comparison.
- For deeper coverage of these names, explore BIIB Major News and BIIB Today's Price Move, as well as PFE Major News and PFE Today's Price Move.
- To see which automated strategies are currently best positioned for market conditions, explore Trending AI Robots.
Introduction
Biogen and Pfizer are two of the most closely watched names in the pharmaceutical sector, yet they occupy very different positions in the current market cycle. Biogen is a biotechnology company focused on neuroscience, rare diseases, and immunology, while Pfizer is a diversified global pharmaceutical giant spanning oncology, vaccines, immunology, and cardiovascular care. This stock comparison is relevant for investors weighing a growth-oriented biotech turnaround against a high-yield, large-cap drugmaker navigating a patent cliff. Traders and long-term investors alike may find value in examining how each company's relative performance, business model, and catalysts shape its market positioning in the current environment.
BIIB Overview and Recent Performance
Biogen has demonstrated a notable turnaround in recent quarters after several difficult years defined by declining multiple sclerosis (MS) revenue and pipeline skepticism. In its latest quarterly report, total revenue rose 11% year over year to roughly $2.8 billion, while adjusted earnings per share (EPS) of $2.62 handily beat analyst expectations. A key driver has been the company's "growth portfolio," which surged roughly 49% year over year and now represents about half of core pharmaceutical revenue. Products such as Leqembi (an Alzheimer's treatment developed with partner Eisai), Spinraza (for spinal muscular atrophy), Skyclarys, and Zurzuvae have posted strong double-digit growth, offsetting a 13% decline in legacy MS sales.
Despite the top-line strength, the latest quarter swung to a reported net loss of about $20.6 million, driven largely by acquired in-process research and development (IPR&D) and milestone charges tied to recent deals, including the acquisition of Apellis Pharmaceuticals. Free cash flow remained healthy, however, supporting liquidity. Over recent weeks, the stock has shown notable strength, climbing substantially year to date and trading above its key moving averages, with a high relative strength reading. Analysts have responded with a consensus "Buy" rating and an average price target near $264. Sentiment has improved on growing confidence in the late-stage pipeline, with upcoming lupus study readouts serving as a key catalyst.
PFE Overview and Recent Performance
Pfizer is among the world's largest pharmaceutical companies, with a diversified portfolio spanning oncology, vaccines, immunology, and cardiovascular medicines. Its recent performance has been defined by a post-pandemic reset: COVID-19 products such as Comirnaty and Paxlovid continue to decline sharply, while the company works to grow newer and acquired products, including oncology treatments Padcev and Lorbrena and migraine drug Nurtec ODT. Recent quarters have been mixed, with a large non-cash intangible asset write-down of roughly $4.3 billion contributing to a quarterly net loss, even as revenue held broadly steady.
Over recent weeks, Pfizer shares have climbed roughly 20% year to date and reached a 52-week high, reflecting improving sentiment around cost-cutting, pipeline progress, and the company's re-entry into the obesity market through the Metsera acquisition. The stock also carries an attractive dividend yield near 5.8%, backed by a long history of consecutive quarterly payouts. However, the company faces a looming loss of exclusivity on several flagship drugs, and analysts expect EPS to decline in the near term. Wall Street's consensus rating sits at "Hold," with an average price target slightly below recent trading levels, reflecting a balance between income appeal and structural headwinds.
Trending AI Robots
For traders seeking a more systematic approach to this type of stock comparison, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a much larger universe of available strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of different tickers, each built around distinct trading styles, timeframes, strategies, and performance statistics. Because only a subset of these bots is well-suited to current market conditions at any given moment, the Trending AI Robots section highlights the strategies currently demonstrating the strongest alignment with the market. The bots vary widely in their approach, from short-term swing trading to longer-horizon trend following. Exploring this curated list can help investors identify automated strategies that match their own risk tolerance and objectives.
Head-to-Head Comparison
The two companies differ sharply in business model and growth profile. Biogen is a smaller, more focused biotech whose thesis hinges on a successful pivot from a declining MS franchise to newer neuroscience and rare-disease products. Pfizer is a diversified mega-cap whose narrative centers on replacing lost COVID-19 revenue and managing a patent cliff through acquisitions and cost discipline.
On momentum, Biogen holds the edge. Its stock has outperformed on a year-to-date basis, enjoys a consensus "Buy" rating, and benefits from identifiable near-term catalysts, including lupus trial readouts and continued Leqembi adoption. Pfizer, by contrast, offers a far higher dividend yield and defensive scale, but its relative performance has been more modest and its analyst consensus is "Hold."
Risk profiles also diverge. Biogen carries concentration risk in its growth products and faces uncertainty around pipeline trial outcomes, while Pfizer's principal risks stem from patent expirations and declining COVID product sales. Sector exposure is similar — both are healthcare — but Biogen skews toward high-risk, high-reward innovation, whereas Pfizer emphasizes scale, income, and diversification.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, analyst sentiment, and catalyst positioning, Tickeron's AI would currently lean toward Biogen (BIIB) in this comparison. Biogen's steadier uptrend, double-digit revenue growth, consensus "Buy" rating, and identifiable near-term catalysts give it a relatively stronger technical and fundamental setup than Pfizer's, which is tempered by a "Hold" consensus and an approaching patent cliff. That said, this is a probabilistic assessment, not a definitive forecast. Pfizer's dividend yield and defensive scale remain meaningful counterweights, and either name could shift positioning as new clinical or regulatory data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and PFE is a Hold.
Momentum Indicator for BIIB turns negative, indicating new downward trend
BIIB saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 58 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 17 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 58 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 37 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 165 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.947) is normal, around the industry mean (-1.421). P/E Ratio (43.724) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
PFE sees MACD Histogram just turned negative
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 30 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 195 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
BIIB | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 84 | 83 | |
PRICE GROWTH RATING 1..100 | 9 | 27 | |
P/E GROWTH RATING 1..100 | 3 | 4 | |
SEASONALITY SCORE 1..100 | 50 | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (76) in the Biotechnology industry is in the same range as PFE (96) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PFE (100) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
PFE's SMR Rating (83) in the Pharmaceuticals Major industry is in the same range as BIIB (84) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (9) in the Biotechnology industry is in the same range as PFE (27) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
BIIB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as PFE (4) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
| BIIB | PFE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 61% | 4 days ago 54% |
| Stochastic ODDS (%) | 4 days ago 64% | 4 days ago 55% |
| Momentum ODDS (%) | 4 days ago 68% | 4 days ago 53% |
| MACD ODDS (%) | 4 days ago 62% | 4 days ago 67% |
| TrendWeek ODDS (%) | 4 days ago 68% | 4 days ago 56% |
| TrendMonth ODDS (%) | 4 days ago 65% | 4 days ago 48% |
| Advances ODDS (%) | 11 days ago 59% | 8 days ago 54% |
| Declines ODDS (%) | 7 days ago 67% | 4 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 65% | N/A |
| Aroon ODDS (%) | 4 days ago 62% | 4 days ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- BIIB’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 2 TA indicator(s) are bullish while PFE’s TA Score has 2 bullish TA indicator(s).
- BIIB’s TA Score: 2 bullish, 6 bearish.
- PFE’s TA Score: 2 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -2.08% price change this week, while PFE (@Pharmaceuticals: Major) price change was -2.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.88%. For the same industry, the average monthly price growth was +1.80%, and the average quarterly price growth was +5.50%.
Reported Earning Dates
BIIB is expected to report earnings on Feb 17, 2027.
PFE is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.88% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.20% | ||
| BMY - PFE | 60% Loosely correlated | -1.57% | ||
| AMGN - PFE | 53% Loosely correlated | +0.03% | ||
| GSK - PFE | 51% Loosely correlated | -0.16% | ||
| NVS - PFE | 50% Loosely correlated | +0.38% | ||
| BIIB - PFE | 46% Loosely correlated | +1.81% | ||
More | ||||